CHM and pancreatic neoplasm: Therefore, understanding the molecular mechanism for inter-regulation among REP1, mTORC1, and lysosomal degradation pathways would provide an intriguing rationale for targeting for pancreatic cancers with high capacities for lysosomal degradation.